ELANCO ANIMAL HEALTH has been Sued for Securities Fraud after Stock Plummets 21%; Contact the Firm before December 6 Class Action Deadline (NYSE:ELAN)

Lawsuit Overview - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Elanco securities [2] - The case is pending in the U S District Court of Maryland under the caption Barpar v Elanco Animal Health Incorporated et al No 24-cv-02912 [2] Allegations Against Elanco - The complaint alleges that Elanco develops products to treat diseases in animals with two key treatments Zenrelia and Credelio Quattro currently under FDA review [3] - Elanco initially stated that the FDA had all necessary data to complete its review and expected approval before the end of June 2024 [4] - On June 27 2024 Elanco announced that the FDA would not approve either drug in June 2024 and Zenrelia would come with a boxed warning on safety [4] Impact on Stock Price - Following the announcement Elanco's stock price declined over 21 from $17 97 per share on June 26 2024 to$14 27 per share on June 27 2024 [5] Legal Investigation - BFA Law is investigating whether Elanco and certain executives made materially false and/or misleading statements to investors regarding the FDA's approval of its drugs [5] Legal Options for Investors - Investors who suffered losses in Elanco Animal Health Incorporated NYSE ELAN may have legal options and are encouraged to submit their information to BFA Law [6] - Representation is on a contingency fee basis with no cost to shareholders who are not responsible for any court costs or expenses of litigation [6] About Bleichmar Fonti & Auld LLP - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation [7] - The firm was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been recognized as Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters [7] - BFA has achieved notable successes including recovering over $900 million from Tesla Inc's Board of Directors and$420 million from Teva Pharmaceutical Ind Ltd [7]